Executives On The Move: Avidity Biosciences, Exicure and More
Executive Summary
Recent executive moves in the industry include C-suite changes at Avidity Biosciences and BioAtla. Meanwhile, new directors were appointed at Exicure and Alimera Sciences.
You may also be interested in...
Pipeline Watch - ADD Meeting Dominates Phase III Readouts
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.
Seagen Deal Ticks The Big Three For Pfizer: Revenues, Pipeline, Platform
Pfizer expects Seagen’s portfolio of approved drugs and development pipeline to add $10bn in annual revenue by 2030.
Pipeline Watch: Eight Approvals And 12 Phase III Trial Updates
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.